January 09, 2014
1 min read

Glaucoma drug candidate shows low systemic exposure, IOP reduction

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Top-line results from a phase 1 pharmacokinetics study showed that a glaucoma drug being developed by Aerie Pharmaceuticals seems to have a low systemic exposure, a high safety profile and an effective IOP-lowering capability, according to a press release.

The drug, AR-13324, was administered as an eye drop to 18 healthy subjects once daily for 8 days. Blood levels after administration were at or below the limit of detection at all time points, and no drug-related effects on systemic safety parameters were observed, according to the release.

Before dosing, all subjects had normotensive IOPs ranging from 12 mm Hg to 21 mm Hg, with a mean diurnal IOP of approximately 16 mm Hg. After 8 days of dosing, mean diurnal IOP dropped to 11 mm Hg, a more than 30% reduction, the release said.

The completion of this study paves the way for two planned phase 3 registration studies of AR-13324, which are expected to begin by mid-year.